Terms: = Prostate cancer AND PIK3CA, MGC142161, 5290, ENSG00000121879, P42336, MGC142163, p110-alpha, PI3K
1534 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Research of the unrecognised functions of miR-375 in prostate cancer cells.
Goztepe M; Eroglu O
Cell Mol Biol (Noisy-le-grand); 2024 Mar; 70(3):212-218. PubMed ID: 38650131
[TBL] [Abstract] [Full Text] [Related]
3. [Explore the mechanism of astragaloside IV-PESV on proliferation, migration, and autophagy of prostate cancer cells based on the pi3k/AKT signaling pathway].
You XJ; Wen Z; Zheng QX; Li QX; Fu W; Li HS; Wang B
Zhonghua Nan Ke Xue; 2023 Dec; 29(12):963-972. PubMed ID: 38639947
[TBL] [Abstract] [Full Text] [Related]
4. Lapatinib antitumor effect is associated with pi3k and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
5. The interplay between autophagy and ferroptosis presents a novel conceptual therapeutic framework for neuroendocrine prostate cancer.
Wang Y; Wu N; Li J; Liang J; Zhou D; Cao Q; Li X; Jiang N
Pharmacol Res; 2024 May; 203():107162. PubMed ID: 38554788
[TBL] [Abstract] [Full Text] [Related]
6. Microbiome Dysbiosis Is Associated with Castration Resistance and cancer Stemness in Metastatic prostate cancer.
Uzelac M; Xin R; Ongkeko WM
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542265
[TBL] [Abstract] [Full Text] [Related]
7. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
8. Network pharmacology and experimental evaluation strategies to decipher the underlying pharmacological mechanism of Traditional Chinese Medicine CFF-1 against prostate cancer.
Wei Y; Zhu M; Chen Y; Ji Q; Wang J; Shen L; Yang X; Hu H; Zhou X; Zhu Q
Aging (Albany NY); 2024 Mar; 16(6):5387-5411. PubMed ID: 38484140
[TBL] [Abstract] [Full Text] [Related]
9. Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C; Williamson SC; Hopcroft L; Ros S; Moss JI; Kerr J; van Weerden WM; de Bruin EC; Dunn S; Willis B; Ross SJ; Rooney C; Barry ST
Br J Cancer; 2024 May; 130(8):1377-1387. PubMed ID: 38396173
[TBL] [Abstract] [Full Text] [Related]
10. Capivasertib: First Approval.
Shirley M
Drugs; 2024 Mar; 84(3):337-346. PubMed ID: 38388873
[TBL] [Abstract] [Full Text] [Related]
11. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract] [Full Text] [Related]
12. Development of certain benzylidene coumarin derivatives as anti-prostate cancer agents targeting EGFR and pi3kβ kinases.
Elagawany M; Abdel Ghany LMA; Ibrahim TS; Alharbi AS; Abdel-Aziz MS; El-Labbad EM; Ryad N
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2311157. PubMed ID: 38348846
[TBL] [Abstract] [Full Text] [Related]
13. Integrated analysis identifies GABRB3 as a biomarker in prostate cancer.
Chen JY; Chang CF; Huang SP; Huang CY; Yu CC; Lin VC; Geng JH; Li CY; Lu TL; Bao BY
BMC Med Genomics; 2024 Jan; 17(1):41. PubMed ID: 38287309
[TBL] [Abstract] [Full Text] [Related]
14. Leptin promotes proliferation of human undifferentiated spermatogonia by activating the pi3k/AKT/mTOR pathway.
Xin S; Xiaoxuan L; Yixuan Z; Zhikang C
Am J Reprod Immunol; 2024 Jan; 91(1):e13811. PubMed ID: 38282611
[TBL] [Abstract] [Full Text] [Related]
15. Activation of cytotoxic lymphocytes through CD6 enhances killing of cancer cells.
Gurrea-Rubio M; Wu Q; Amin MA; Tsou PS; Campbell PL; Amarista CI; Ikari Y; Brodie WD; Mattichak MN; Muraoka S; Randon PM; Lind ME; Ruth JH; Mao-Draayer Y; Ding S; Shen X; Cooney LA; Lin F; Fox DA
Cancer Immunol Immunother; 2024 Jan; 73(2):34. PubMed ID: 38280067
[TBL] [Abstract] [Full Text] [Related]
16. Dual targeting of the androgen receptor and pi3k/AKT/mTOR pathways in prostate cancer models improves antitumor efficacy and promotes cell apoptosis.
Sugawara T; Nevedomskaya E; Heller S; Böhme A; Lesche R; von Ahsen O; Grünewald S; Nguyen HM; Corey E; Baumgart SJ; Georgi V; Pütter V; Fernández-Montalván A; Vasta JD; Robers MB; Politz O; Mumberg D; Haendler B
Mol Oncol; 2024 Mar; 18(3):726-742. PubMed ID: 38225213
[TBL] [Abstract] [Full Text] [Related]
17. Antitumor Activity and Mechanism of Terpenoids in Seaweeds Based on Literature Review and Network Pharmacology.
Chen B; Li Y; Li W; Ye S; Zhu L; Ding Y
Adv Biol (Weinh); 2024 Mar; 8(3):e2300541. PubMed ID: 38134388
[TBL] [Abstract] [Full Text] [Related]
18. Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/pi3k Pathway Alterations and Advanced Solid Malignancies.
Subbiah V; Coleman N; Piha-Paul SA; Tsimberidou AM; Janku F; Rodon J; Pant S; Dumbrava EEI; Fu S; Hong DS; Zhang S; Sun M; Jiang Y; Roszik J; Song J; Yuan Y; Meric-Bernstam F; Naing A
Cancer Res Commun; 2024 Feb; 4(2):378-387. PubMed ID: 38126764
[TBL] [Abstract] [Full Text] [Related]
19. TRAIP suppressed apoptosis and cell cycle to promote prostate cancer proliferation via TRAF2-pi3k-AKT pathway activation.
Gu Y; Liang C
Int Urol Nephrol; 2024 May; 56(5):1639-1648. PubMed ID: 38100027
[TBL] [Abstract] [Full Text] [Related]
20. A narrative review on Naringin and Naringenin as a possible bioenhancer in various drug-delivery formulations.
Ganesh P; Suresh V; Narasimhan MK; Sabarathinam S
Ther Deliv; 2023 Dec; 14(12):763-774. PubMed ID: 38088094
[TBL] [Abstract] [Full Text] [Related]
[Next]
